

JUST DROP IT.

THE FIRST
FDA-APPROVED
EYE DROP
EMETIC FOR
DOGS

Clevor[®]

(ropinirole ophthalmic solution)

KEY FEATURE 1:

Unique ocular administration

KEY FEATURE 2:

Convenient, ready-to-use dropper

KEY FEATURE 3:

Fast onset of action and short duration of vomiting proven in a clinical study¹

BENEFIT:

Makes the process of inducing emesis easy and injection free — resulting in a quicker, less stressful process for veterinarians, their staff, and pet owners.

BENEFIT:

No complicated dose calculations or additional disposables — such as syringes or needles — required. No need to be resuspended or crushed to be administered.

BENEFIT:

Inducing emesis is a time sensitive, critical first step in the decontamination process. Clevor is a dog friendly choice for initiating that process quickly.

CLEVOR[®] is indicated for the induction of vomiting in dogs.

IMPORTANT SAFETY INFORMATION: Do not use in dogs with central nervous system depression or seizures. Do not use in cases of ingestion of sharp foreign objects, corrosive agents (acids or alkalis), volatile substances or organic solvents. CLEVOR[®] should not be administered in cases with corneal ulceration, ocular irritation, or ocular injury. Do not use when there is a known sensitivity to ropinirole or the inactive ingredients. **ADVERSE REACTIONS MAY INCLUDE:** Transient mild or moderate hyperemia of the eye, ocular discharge, protrusion of the 3rd eyelid and blepharospasm, transient mild lethargy and increased heart rate. Not recommended for use in breeding, pregnant or lactating dogs. CLEVOR[®] has not been evaluated in dogs with heart or liver impairments or dogs younger than 4.5 months or less than 4 pounds. Dopamine antagonists, neuroleptics and other medicines with antiemetic properties may reduce the effectiveness of ropinirole. CLEVOR[®] should be administered by a veterinary professional. Gloves and protective eyewear should be worn when administering. Not for use in humans. Keep out of reach of children. For complete product safety information, see brief on following page or visit www.vetoquinolusa.com/clevor-info.

¹Suokko, M., et al. (2020) Ropinirole eye drops induce vomiting effectively in dogs: a randomised, double-blind, placebo-controlled clinical study. Vet Rec., Mar 7;186(9):283.

CLEVOR[®] is a trademark of Orion Corporation. It is manufactured by Orion Corporation and distributed by Vetoquinol USA under license from Orion Pharma Animal Health. CVR-0378-SNDBTE

sound
byte

Clevor[®]

(ropinirole ophthalmic solution)

When dogs eat something potentially poisonous or harmful, you need to act quickly. Clevor is a selective emetic with a fast onset of action and short duration of vomiting. A convenient, single-use dropper provides one injectionless treatment for a dog.

Clevor - a new way to induce emesis in dogs.



sound byte

CHECK-OFF &
ECHO NOTES

First, always ask if a Vetoquinol Territory Manager has been in contact recently:

Doctor, have you recently been introduced to Clevor, the first and only FDA-approved product for emesis induction in dogs?

If **YES**, confirm and discuss benefits.

If **NO**, engage/detail the customer as the primary contact.

Confidence

I believe Clevor will be a great addition to your clinic because it offers a quicker, less stressful option for inducing emesis in dogs.

Neutral invitation

Let's take a look at some basic information about Clevor.

It's the customer's decision

You can feel confident in administering Clevor in situations where you need a quick, reliable emetic.

CLEVOR®

(ropinirole ophthalmic solution)

30 mg/mL

For ophthalmic use in dogs only

Single use dropper

BRIEF SUMMARY: Before using CLEVOR® (ropinirole ophthalmic solution), please consult the product insert, a summary of which follows:

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATION:

For induction of vomiting in dogs.

DOSAGE AND ADMINISTRATION:

This product should be administered by veterinary personnel.

Dosing Instructions:

Administer the appropriate number of eye drops typically according to Table 1. The number of eye drops administered corresponding to body weight results in a target dose of 3.75 mg/m² (dose band 2.7 - 5.4 mg/m²). If the dog does not vomit within 20 minutes of the first dose, then a second dose may be administered.

Table 1. Dose Administration

Body weight in kilograms	Body weight in pounds	Total number of eye drops	Example administration
1.8 - 5	4 - 11.1	1	1 drop into either left or right eye
5.1 - 10	11.2 - 22.1	2	1 drop each eye
10.1 - 20	22.2 - 44.1	3	2 drops in one eye and 1 drop in the other eye
20.1 - 35	44.2 - 77.2	4	2 drops in each eye
35.1 - 60	77.3 - 132.3	6	An initial dose of 2 drops in each eye, followed 2 minutes later by 1 drop in each eye
60.1 - 100	132.4 - 220.5	8	An initial dose of 2 drops in each eye, followed 2 minutes later by 2 drops in each eye

Dose Administration:



- Wear gloves and protective eye wear when handling or administering this product to prevent accidental exposure.
- Open the dropper by twisting off the tail.



- Keep the dog's head steady in a slightly upright position.
- Hold the dropper in an upright position without touching the eye.
- Rest your finger on the forehead of your dog to maintain the distance between the dropper and the eye.
- Squeeze the prescribed number of drops in to the eye(s).



- CLEVOR is a single use dropper and is light sensitive.
- After administration, with gloves on, return the dropper to the aluminum pouch and place in the carton.



- If the dog does not vomit, a second dose can be given 20 minutes after administration of the first dose.
- This second dose is the same number of drops as the first dose.
- Thirty minutes after opening, with gloves on, dispose of dropper, aluminum pouch, and carton.

Refer to the **Animal Safety Warnings** section for treatment of protracted vomiting.

CONTRAINDICATIONS:

Do not use in dogs with central nervous system depression or seizures.
Do not use in cases of ingestion of sharp foreign objects, corrosive agents (acids or alkalis), volatile substances or organic solvents.
Do not use in cases with corneal ulceration, ocular irritation, or ocular injury.
Do not use when there is a known sensitivity to ropinirole or the inactive ingredients.

WARNINGS:

Human Safety Warnings:

Not for use in humans. Keep out of reach of children.

Wear gloves and protective eye wear when handling or administering this product to prevent accidental exposure. In case of accidental eye, oral or skin exposure, flush with water. If wearing contact lenses, eyes should be rinsed first, then remove contact lenses and continue rinsing. Remove contaminated clothing. Ropinirole is a dopamine agonist. **Seek medical attention if accidental exposure occurs and show the package insert or label to the physician.** Exposure to this drug may cause adverse reactions such as headache, nausea, vomiting, dizziness, orthostatic hypotension, and sleepiness. Avoid contact with the product if pregnant, planning to become pregnant, or breast-feeding, as exposure has been shown to have adverse effects on embryo-fetal development based on rodent studies.

Animal Safety Warnings:

This product should be administered by veterinary personnel.
Dogs should be monitored for CLEVOR-associated clinical signs, including protracted vomiting, salivation, muscle tremors, evidence of abdominal discomfort, lethargy, transient tachycardia, transient decrease in blood pressure and signs of ocular irritation, including conjunctival hyperemia, mild blepharospasm, and protrusion of the third eyelid. These clinical signs are related to the pharmacological action of ropinirole.
To stop protracted vomiting, administer metoclopramide (dopamine D2 antagonist) at a dose of 0.5 mg/kg intravenously (IV) or subcutaneously (SQ). Metoclopramide also decreases the prevalence of most CLEVOR-associated clinical signs.

PRECAUTIONS:

The safe use of CLEVOR has not been evaluated in dogs with cardiac disease or cardiovascular compromise. CLEVOR can cause transient tachycardia and transient decreased systolic blood pressure.
The safe use of CLEVOR has not been evaluated in dogs with hepatic impairment. CLEVOR is metabolized by the liver.
The safe use of CLEVOR has not been evaluated in dogs younger than 4.5 months of age and weight less than 4 pounds.
The safe use of CLEVOR has not been evaluated in dogs that are pregnant, lactating, or intended for breeding.

ADVERSE REACTIONS:

Safety was evaluated during a field study that enrolled 132 dogs (100 in the CLEVOR group and 32 in the vehicle control group). CLEVOR was administered as drops into the eyes at the dose as directed by the dosing table (see **DOSAGE AND ADMINISTRATION**). The following table shows the number of dogs exhibiting ocular, systemic, and clinical pathology adverse reactions.

Table 2: Adverse Reactions Reported During the Study (all dogs)

Organ System	Adverse Reaction	CLEVOR (N=100)	Vehicle control (N=32)
Ocular	Conjunctival hyperemia ^a	51 (51%)	6 (19%)
	Protrusion of the third eyelid ^a	38 (38%)	1 (3%)
	Conjunctival discharge ^a	30 (30%)	1 (3%)
	Blepharospasm ^a	19 (19%)	0
	Conjunctival swelling ^a	3 (3%)	0
	Scratching/rubbing of eyes ^a	4 (4%)	0
	Corneal ulceration	1 (1%)	0
	Corneal fluorescein uptake without corneal ulceration	1 (1%)	0
Systemic	Lethargy	41 (41%)	0
	Tachycardia (>160 beats per minute) ^{a,b}	14 (14%)	0
	Vomiting duration longer than one hour	8 (8%)	0
	Salivation	3 (3%)	1 (3%)
	Trembling	3 (3%)	0
	Diarrhea or soft stool	2 (2%)	1 (3%)
	Anxious	1 (1%)	0
	Borborygmi	1 (1%)	0
Clinical Pathology	Crystalluria ^c	13 (20%)	3 (15%)
	Pyuria ^c	12 (18%)	3 (15%)
	Increased liver enzymes ^d	3 (3%)	0
	Decreased blood glucose	2 (2%)	0
	Increased prothrombin time	1 (1%)	0

^a Assessment performed 30 minutes after dose administration

^b Tachycardia resolved for most dogs within 4 hours after dose administration

^c Urinalysis results were reported for only 86 dogs (66 administered CLEVOR and 20 control)

^d All three dogs had elevated alanine aminotransferase. Additionally, one of the dogs also had an elevated aspartate aminotransferase and another of the dogs also had an elevated alkaline phosphatase and total bilirubin.

Note: If any animal experienced the event more than once, only the first occurrence was tabulated.

To report suspected adverse events call 1 (800) 835-9496, for technical assistance or to obtain a copy of the SDS, contact Vetoquinol USA, Inc. at 1 (800) 267-5707 or www.vetoquinolusa.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

CLEVOR is a trademark of Orion Corporation

Manufactured by:
Orion Corporation

Distributed by:
Vetoquinol USA, Inc.
Ft. Worth, TX (USA) 76137
1 (800) 267-5707
www.vetoquinolusa.com

Issued 06/2020

Approved by FDA under NADA # 141-534

ORION
PHARMA

vetoquinol